Actively Recruiting
A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
Led by Aibin Liang，MD，Ph.D. · Updated on 2025-01-03
24
Participants Needed
1
Research Sites
80 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
CONDITIONS
Official Title
A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must voluntarily sign the informed consent form and agree to follow the study schedule and long-term follow-up for up to 15 years
- Age between 18 and 75 years
- Histologically or cytologically confirmed B-cell Non-Hodgkin Lymphoma
- Previously received at least two lines of systemic therapy
- Intolerance to last treatment or disease progression requiring therapy
- Presence of measurable target lesions
- Expected survival greater than 12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Female participants of childbearing potential must have a negative pregnancy test before preconditioning therapy and agree to use effective contraception for 1 year after treatment; male participants must use effective contraception for 1 year after treatment and avoid sperm donation during this time
You will not qualify if you...
- Pregnant or lactating women
- HIV, syphilis infection, active hepatitis B or C virus infection
- Uncontrolled active infections including active tuberculosis
- Toxicities from previous treatments not resolved to grade 1 or less, except alopecia and other tolerable events
- Received treatment for the disease within 14 days before informed consent, except limited radiotherapy
- Use of systemic glucocorticoids equivalent to more than 15 mg/day prednisone within 7 days prior to informed consent, except topical glucocorticoids
- Vaccination with live attenuated, inactivated, or RNA vaccines within 4 weeks prior to informed consent
- Allergy or intolerance to preconditioning drugs or tocilizumab or history of severe allergy
- Heart disease within 6 months prior to screening
- Oxygen saturation below 92%
- Presence of a second primary malignancy requiring treatment or not in remission within past 2 years
- Major surgery within 2 weeks before informed consent or planned during the study or within 4 weeks after treatment, excluding local anesthesia
- Unable or unwilling to comply with study protocol or deemed unsuitable by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Tongji Hospital
Shanghai, Shanghai Municipality, China, 200065
Actively Recruiting
Research Team
A
Aibin Liang MD,Ph.D.
CONTACT
P
Ping Li MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here